Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Arthroplasty, Replacement Clinical Trial

Official title:

An Open Label, Non-comparative, Pharmacokinetic and Pharmacodynamic Study to Evaluate the Effect of Dabigatran Etexilate on Coagulation Parameters Including a Calibrated Thrombin Time Test in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Primary Unilateral Elective Total Knee or Hip Replacement Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01184989
• Other study ID #: 1160.86
• Secondary ID: 2010-018723-26
• Status: Completed
• Phase: Phase 4
• Start date: August 2010
• Est. completion date: April 2013

Study information

• Verified date: August 2018
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip- or knee-replacement surgery, this PK/PD study will be conducted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 142
• Est. completion date: April 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Patients scheduled for primary unilateral elective total knee or hip replacement, male or female being 18 years or older

2. Moderate renal impairment (CrCl 30-50 mL/min)

3. Written informed consent

4. Caucasian patients

Exclusion criteria:

1. Patients weighing less than 40 kg.

2. Patients requiring chronic treatment with anticoagulants (e.g. vitamin K antagonists; e.g. patients with atrial fibrillation, patients with artificial heart valves, etc.).

3. Patients who in the investigator's judgment were perceived as having an excessive risk of bleeding, for example:

Constitutional or acquired coagulation disorders

History of bleeding diathesis

Clinically relevant bleeding (gastrointestinal, pulmonary, intraocular or urogenital bleeding) within 3 months of enrolment

Major surgery or trauma (e.g. hip fracture) within 3 months of enrolment

History of thrombocytopenia, including heparin-induced thrombocytopenia, or a platelet count <100 000 cells/microliter at randomization

Any history of hemorrhagic stroke or any of the following intracranial pathologies:

bleeding, neoplasm

Any arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities

Presence of malignant neoplasms at higher risk of bleeding

Known or suspected oesophageal varices

Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 days

Treatment with anticoagulants, clopidogrel, ticlopidine, abciximab, aspirin >162.5 mg/day or non-steroidal anti-inflammatory drug (NSAID) with t1/2>12 hours within 7 days prior to hip or knee replacement surgery OR anticipated need while the patient was receiving study medication and prior to 24 hours after the last administration of study medication (COX-2 selective inhibitors are allowed) because of anticipated need of quinidine, verapamil or other restricted medication during the treatment period

4. Recent unstable cardiovascular disease (in the investigator's opinion) such as uncontrolled hypertension, that was ongoing at the time of enrolment or history of myocardial infarction within 3 months of enrolment.

5. Ongoing treatment for VTE.

6. Liver disease expected to have any potential impact on survival (i.e. hepatitis B or C, cirrhosis) or ALT/AST >3x upper limit of normal range (ULN). This did not include Gilbert's syndrome or hepatitis A with complete recovery.

7. Known severe renal insufficiency (CrCl <30 mL/min) and patients with mild renal insufficiency (CrCl >50 mL/min) or normal renal function.

8. Planned anaesthesia with post-operative indwelling epidural catheters.

9. Pre-menopausal women (last menstruation <=1 year prior to signing informed consent), who were:

Pregnant

Nursing

Of child-bearing potential and were NOT practicing acceptable methods of birth control, or did NOT plan to continue practicing an acceptable method throughout the study. Acceptable methods of birth control included intrauterine device; oral, implantable or injectable contraceptives and surgical sterility

10. Hypersensitivity to dabigatran etexilate or to any of excipients.

11. Participation in a clinical trial within 30 days of enrolment.

12. Known alcohol or drug abuse which would interfere with completion of the study; patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration.

13. Previous participation in this study.

Related Conditions & MeSH terms

• Arthroplasty, Replacement
• Moderate Renal Impairment (CrCl 30-50 mL/Min)
• Prevention of Venous Thromboembolism
• Renal Insufficiency
• Thromboembolism
• Venous Thromboembolism

Intervention

Drug:
• Dabigatran etexilate
once daily approved dose by EMEA and Health Canada

Locations

Country	Name	City	State
Austria	1160.86.43001 Boehringer Ingelheim Investigational Site	Graz
Austria	1160.86.43003 Boehringer Ingelheim Investigational Site	Wien
Canada	1160.86.01003 Boehringer Ingelheim Investigational Site	Charlottetown	Prince Edward Island
Canada	1160.86.01002 Boehringer Ingelheim Investigational Site	Halifax	Nova Scotia
Canada	1160.86.01001 Boehringer Ingelheim Investigational Site	Red Deer	Alberta
Czechia	1160.86.42002 Boehringer Ingelheim Investigational Site	Prague 5
Finland	1160.86.35801 Boehringer Ingelheim Investigational Site	Jyväskylä
Netherlands	1160.86.31002 Boehringer Ingelheim Investigational Site	Hilversum
Sweden	1160.86.46002 Boehringer Ingelheim Investigational Site	Hässleholm
Sweden	1160.86.46001 Boehringer Ingelheim Investigational Site	Mölndal

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

Austria,  Canada,  Czechia,  Finland,  Netherlands,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dabigatran Concentration in Plasma, Estimated From Local Hemoclot®	The Hemoclot® test kit measures the dTT (diluted Thrombin time). In the present trial, as a first step, the dTT in calibration samples that had known Dabigatran concentrations was measured locally with the Hemoclot® test kit, and a linear calibration curve was fitted to the data from the calibration samples. Thereafter, for each patient at each time-point, the dTT was measured with the Hemoclot® kit and the Dabigatran concentration was read off from the calibration curve.; These estimated concentrations are compared with concentrations measured in parallel with HPLC-MS/MS.; As the trial objective is the method comparison and not the detection of the absolute concentrations of either of the methods, the result is reported as a relative bioavailability [%], see "Statistical Analysis 1" below. Only concentrations >= LLOQ (Lower Limit of concentration) are included in the quantitative comparison.	Screening, day of surgery 1 hour (h) and 2h after drug intake (di) for late finalization of surgery, 4h and 8h after di for early finalization of surgery, 15 minutes (min) before di at days 2, 3, 4, 5 and 6, at day 6 also 1h, 2h, 4h, 8h and 24 after di
Primary	Dabigatran Concentration in Plasma, Estimated From Central Hemoclot®	The Hemoclot® test kit measures the dTT (diluted Thrombin time). In the present trial, as a first step, the dTT in calibration samples that had known Dabigatran concentrations was measured centrally with the Hemoclot® test kit, and a linear calibration curve was fitted to the data from the calibration samples. Thereafter, for each patient at each time-point, the dTT was measured with the Hemoclot® kit and the Dabigatran concentration was read off from the calibration curve.; These estimated concentrations are compared with concentrations measured in parallel with HPLC-MS/MS.; As the trial objective is the method comparison and not the detection of the absolute concentrations of either of the methods, the result is reported as a relative bioavailability [%], see "Statistical Analysis 1" below. Only concentrations >= LLOQ (Lower Limit of concentration) are included in the quantitative comparison.	Screening, day of surgery 1 hour (h) and 2h after drug intake (di) for late finalization of surgery, 4h and 8h after di for early finalization of surgery, 15 minutes (min) before di at days 2, 3, 4, 5 and 6, at day 6 also 1h, 2h, 4h, 8h and 24 after di
Primary	Dabigatran Concentration in Plasma, Measured With HPLC-MS/MS	Dabigatran Concentration in Plasma, measured with HPLC-MS/MS - Most relevant timepoints are reported here, ie timepoints of day 6	At day 6 before drug intake (di), at 1h, 2h, 4h, 8h and 24h after di